25I-NBF

25I-NBF
Clinical data
ATC code	none;
Legal status
Legal status	BR: Class F2 (Prohibited psychotropics); DE: NpSG (Industrial and scientific use only); UK: Class A;
Identifiers
	IUPAC name 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-fluorophenyl)methyl]ethan-1-amine;
CAS Number	919797-21-0 ;
PubChem CID	57469209;
ChemSpider	24751866 ;
UNII	MR8FRH5W3C;
CompTox Dashboard (EPA)	DTXSID00726753 ;
Chemical and physical data
Formula	C17H19FINO2
Molar mass	415.247 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1cc(I)c(OC)cc1CCNCc2ccccc2F;
	InChI InChI=1S/C17H19FINO2/c1-21-16-10-15(19)17(22-2)9-12(16)7-8-20-11-13-5-3-4-6-14(13)18/h3-6,9-10,20H,7-8,11H2,1-2H3 ; Key:LPBKNBHMWRBPHT-UHFFFAOYSA-N ;
	(what is this?) (verify)

25I-NBF (2C-I-NBF, NBF-2C-I, Cimbi-21) is a derivative of the phenethylamine hallucinogen 2C-I, which acts as a highly potent partial agonist for the human 5-HT_2A receptor,^[2]^[3]^[4] with bias towards the β-arrestin 2 coupled signalling pathway.^[5] It has been studied in its ¹¹C radiolabelled form as a potential ligand for mapping the distribution of 5-HT_2A receptors in the brain, using positron emission tomography (PET).^[6]^[7]